Home / Insights / How Alzheimer’s Disease Changes the Brain

Neurobiology

How Alzheimer’s Disease Changes the Brain

What begins as microscopic changes in proteins and cell signaling can, over years, disrupt the brain’s communication networks and reshape the systems that support memory, reasoning, language, and behavior.

6–8 minute read

Alzheimer’s disease is often recognized through memory problems, but the disease itself begins at a much smaller scale. Proteins change shape. Synapses — the contact points neurons use to communicate — become less efficient. Immune cells alter their behavior. Networks that once moved information rapidly between brain regions become less coordinated. Over time, vulnerable neurons are injured and lost.

The familiar symptoms of Alzheimer’s are the visible result of this deeper biological process. Understanding that process also explains why a single plaque, scan, or symptom never tells the whole story: Alzheimer’s develops through interacting changes that unfold across different brain regions and at different rates.

The brain is a network, not a filing cabinet

Memory is not stored in one isolated place. Forming a new memory requires coordinated activity across the hippocampus, nearby temporal-lobe structures, and wider cortical networks. Attention, language, planning, navigation, emotion, and decision-making depend on overlapping circuits of their own.

That network perspective matters because Alzheimer’s does not simply “erase memories.” It progressively weakens the cells and connections that allow different brain systems to work together. Early in the disease, a person may repeat a question or struggle to retain recent information. Later, impairment can extend to language, spatial orientation, judgment, behavior, and basic daily activities as more networks are affected.

Amyloid: one of the earliest biological signals

Amyloid-beta is a small protein fragment produced during normal cell activity. In Alzheimer’s disease, certain forms can accumulate and eventually form plaques between neurons. Amyloid is one of the defining biological features of the disease, and modern PET imaging and fluid biomarkers can detect amyloid-related changes in living patients.

But amyloid should not be understood as a pile of debris that mechanically blocks memory. The biology is more complex. Soluble forms of amyloid can interfere with synaptic signaling, and amyloid accumulation appears to interact with tau, immune responses, vascular factors, and other processes. Some people can have substantial amyloid pathology before noticeable cognitive impairment develops.

Tau: when the neuron’s internal support system breaks down

Tau is a protein that normally helps stabilize the internal transport system of neurons. In Alzheimer’s disease, abnormal tau becomes chemically altered and accumulates inside cells as neurofibrillary tangles. These changes interfere with normal neuronal function and are closely associated with the spread of neurodegeneration across connected brain regions.

In general, the regional pattern of tau pathology tracks clinical impairment more closely than amyloid burden does. As tau pathology reaches networks responsible for memory, language, spatial processing, or executive function, the symptoms can increasingly reflect the functions of those networks.

Synapses: where cognitive function starts to fail

Neurons communicate through synapses. These tiny junctions allow electrical and chemical signals to move through brain circuits. In Alzheimer’s disease, synaptic dysfunction can appear early, and progressive synaptic loss is strongly linked with cognitive decline.

This helps explain a clinically important point: a brain can contain abnormal proteins for some time before a person loses independence. The transition from silent biology to noticeable cognitive symptoms depends in part on how effectively neural networks can compensate and how much functional connectivity remains.

The brain’s immune system is part of the story

The brain has its own immune surveillance system. Microglia, specialized immune cells in the central nervous system, normally monitor tissue, respond to injury, and help clear cellular material. In Alzheimer’s disease, microglial states can change around amyloid, injured synapses, and degenerating neurons.

This process is often described as neuroinflammation, but that term can be misleading if it is treated as uniformly harmful. Immune responses can be protective in some contexts and damaging in others. Current research is focused on understanding which microglial responses help contain pathology and which may amplify synaptic injury or chronic inflammation.

Why the hippocampus matters so early

The hippocampus and connected medial temporal-lobe regions are critical for forming and consolidating new memories. These areas are especially vulnerable in the typical amnestic form of Alzheimer’s disease, which is why difficulty learning or retaining recent information is often an early clinical feature.

As the disease progresses into wider cortical networks, the pattern becomes broader. Language may become less precise. Familiar routes may become confusing. Multi-step tasks can become harder to organize. Judgment can change. Eventually, extensive neuronal and synaptic loss can impair even basic self-care.

From biology to everyday symptoms

Brain change	Possible clinical expression
Hippocampal network dysfunction	Repeating questions; forgetting recent conversations
Language-network involvement	Word-finding difficulty; trouble following complex conversation
Parietal/spatial network dysfunction	Getting lost; difficulty interpreting layouts or distances
Frontal/executive network involvement	Difficulty managing finances, medications, or multi-step tasks
Wider network and neuronal loss	Increasing dependence in daily activities

The brain also shrinks — but atrophy is a downstream effect

As neurons and their connections are lost, affected brain regions can shrink. MRI can reveal patterns of atrophy, including changes in medial temporal structures and, later, more widespread cortical loss. However, brain volume is not a direct readout of Alzheimer’s pathology. Aging, vascular disease, other neurodegenerative disorders, and individual differences can also influence brain structure.

For that reason, clinicians interpret structural imaging alongside the history, cognitive testing, neurological examination, and — when indicated — disease-specific biomarkers rather than treating atrophy on an MRI as a stand-alone diagnosis.

Alzheimer’s rarely happens in biological isolation

Real brains are more complicated than textbook diagrams. Older adults may have Alzheimer’s pathology together with small-vessel vascular disease, Lewy body pathology, TDP-43-related changes, or other age-related brain abnormalities. These mixed pathologies can influence symptoms and the rate of decline.

That is one reason two people with similar amyloid levels may look very different clinically. Cognitive reserve, education, vascular health, coexisting disease, genetics, and the distribution of pathology can all shape how the disease is expressed.

Can the brain compensate?

For a time, the brain can adapt to injury. Healthy networks may recruit alternative pathways, and people with greater cognitive reserve may tolerate a degree of pathology before symptoms become obvious. Compensation is not unlimited, but it helps explain why Alzheimer’s biology can precede dementia and why clinical progression varies from person to person.

This also changes how researchers think about treatment. The goal is no longer only to address symptoms after substantial neuronal loss has occurred. Increasingly, the field aims to identify disease earlier and intervene while more brain function is still preserved.

A more modern view of Alzheimer’s disease

The modern scientific model of Alzheimer’s is not simply “amyloid causes dementia.” It is a network disease involving amyloid, tau, synaptic dysfunction, immune responses, neuronal vulnerability, vascular influences, and time. The 2024 revised diagnostic and staging criteria reflect this biological perspective by incorporating biomarkers that can identify core Alzheimer’s pathology, while clinical symptoms remain essential for understanding how the disease is affecting an individual.

Common questions

Do amyloid plaques automatically mean someone has dementia?

No. Amyloid pathology can be present before noticeable cognitive impairment. Clinical status depends on the broader pattern of brain pathology and function.

Is tau more important than amyloid?

They represent different parts of Alzheimer’s biology. Amyloid is a defining early disease marker, while the distribution of tau often tracks neurodegeneration and clinical impairment more closely. They should not be treated as competing explanations.

Can MRI diagnose Alzheimer’s disease by itself?

Usually not. MRI is valuable for assessing brain structure and excluding or identifying other contributors, but Alzheimer’s diagnosis increasingly integrates clinical evaluation with disease-specific biomarkers when appropriate.

Does neuroinflammation mean ordinary anti-inflammatory drugs treat Alzheimer’s?

No. Neuroinflammation in Alzheimer’s involves complex brain immune biology. Evidence about specific immune pathways does not mean that routine anti-inflammatory medication has been shown to stop Alzheimer’s disease.

The most important takeaway

Alzheimer’s disease changes communication before it destroys independence. Amyloid and tau are central biological features, but cognitive decline emerges through a wider cascade involving synapses, neurons, immune responses, brain networks, and coexisting pathology.

Understanding that cascade is why modern diagnosis increasingly combines what a person experiences with what biomarkers reveal about the brain.

---

Related Insights

Selected References

National Institute on Aging. What Happens to the Brain in Alzheimer’s Disease? Updated January 19, 2024.
National Institute on Aging. What Is Alzheimer’s Disease? Updated March 4, 2025.
Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease. Alzheimer’s & Dementia. 2024.
Tzioras M, McGeachan RI, Durrant CS, Spires-Jones TL. Synaptic degeneration in Alzheimer disease. Nature Reviews Neurology. 2023;19:19–38.
Luan Y, et al. Synaptic loss pattern is constrained by brain connectome and modulated by phosphorylated tau in Alzheimer’s disease. Nature Communications. 2025.
Zhang J, et al. Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies. Signal Transduction and Targeted Therapy. 2024.
Zong S, et al. Microglia and neuroinflammation: function, heterogeneity, and crosstalk. Cellular & Molecular Immunology. 2026.
Alzheimer’s Association. Criteria for Diagnosis and Staging of Alzheimer’s Disease.

March/18/2026